Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%. Radiation therapy (RT) is highly effective in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Preclinical studies have shown that combining RT with PD-L1/PD-1 blockade promotes immunogenic cell death and enhances antigen presentation by dendritic cells, thereby boosting systemic T cell-mediated antitumor responses in mouse models. The addition of CTLA-4 inhibition further enhances antigen cross-priming following RT. Recent retrospective data also indicate that combining RT with immune-oncology agents is associated with improved overall survival and prolonged time to progression compared to RT or immunotherapy alone. However, the clinical benefit and immunologic impact of combining RT with tremelimumab and durvalumab have not yet been evaluated in prospective clinical trials for unresectable HCC. This phase II, single-arm clinical trial aims to assess the safety, efficacy, and immunologic effects of combining proton RT with tremelimumab and durvalumab in patients with unresectable HCC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rozpoznanym rakiem wątroby, którego nie da się operować ani przeszczepić.
- •Rak wątroby potwierdzony badaniami (wynikami badań obrazowych lub histologicznymi).
- •Osoby powyżej 18 roku życia.
- •Pacjenci w dobrym ogólnym stanie zdrowia, zdolni do samodzielnego funkcjonowania.
- •Rak wątroby we wczesnym lub zaawansowanym stadium (według klasyfikacji BCLC B lub C).
- •Dobra czynność wątroby potwierdzona badaniami.
✗ Disqualifies
- •Pacjenci z innymi nowotworami, które nie są wyleczone od co najmniej 2 lat.
- •Pacjenci, którzy wcześniej byli leczeni promieniowaniem w tej samej okolicy wątroby.
- •Pacjenci z aktywną, nieleczoną infekcją wirusowym zapaleniem wątroby typu B lub C.
- •Obecność przerzutów raka do innych narządów, które nie mogą być objęte leczeniem promieniowaniem.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chang Gung Memorial Hospital at Linkou
Taoyuan City, Taiwan
Trial contact
Rodney Cheng-En Hsieh, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.